|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Celgene
| Celgene 1616 Eastlake Ave E Suite 510 Seattle, WA 98102 | |
| | Phone: | (206) 709-6000 | Year Established: | 1986 | Ticker: | CELG | Exchange: | NASDAQ | Main Contact: | Mark J. Alles, President, CEO & Chairman | | Other Contacts: | Peter N. Kellogg, Executive VP & Chief Corporate Strategy Officer Jennifer Dudinak, Pharm.D., Senior VP, Global Regulatory Affairs Rupert Vessey, MA, BM BCh, FRCP, Dphil, Executive VP & President, Research and Early Development Jonathan Biller, Executive VP & General Counsel Scott Smith, President & COO David V. Elkins, Executive VP & CFO
| | Company Description | Celgene is a global, integrated, biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products are REVLIMID® (lenalidomide), THALOMID® /Thalidomide and VIDAZA® (azacitidine for injection). VIDAZA was acquired as part of the purchase of Pharmion effective March 7, 2008. | |
|
|
|
|
|